Latest news with #LucidDiagnostics
Associated Press
27-05-2025
- Business
- Associated Press
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ('Lucid' or the 'Company'), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. 'We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products,' said Dennis McGrath, Lucid's Chief Financial Officer. 'This important milestone is a testament to the significant progress Lucid has made in enhancing shareholder value over the past year. We are confident that it will increase our visibility and access to a broader range of institutional investors.' The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025, this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes. For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the 'Russell Reconstitution' section on the FTSE Russell website. About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information about Lucid, please visit and for more information about its parent company PAVmed, please visit About FTSE Russell FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, 'Risk Factors,' in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE Lucid Diagnostics
Yahoo
14-05-2025
- Business
- Yahoo
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -77.78%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.19, delivering a surprise of -26.67%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Lucid Diagnostics , which belongs to the Zacks Medical - Instruments industry, posted revenues of $0.83 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 36.31%. This compares to year-ago revenues of $1 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Lucid Diagnostics shares have added about 45.4% since the beginning of the year versus the S&P 500's gain of 0.1%. While Lucid Diagnostics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Lucid Diagnostics: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.08 on $1.4 million in revenues for the coming quarter and -$0.32 on $7 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Zomedica Corp. (ZOMDF), is yet to report results for the quarter ended March 2025. The results are expected to be released on May 15. This company is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Zomedica Corp.'s revenues are expected to be $7.78 million, up 24.3% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lucid Diagnostics Inc. (LUCD) : Free Stock Analysis Report Zomedica Corp. (ZOMDF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-03-2025
- Business
- Yahoo
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability
Lucid Diagnostics Revenue: $1.2 million in the fourth quarter. EsoGuard Test Volume: 4,042 tests, representing a 45% growth quarter-on-quarter. Veris Health Financing: $2.4 million private placement at a $35 million pre-money valuation. NIH Grant for Veris: $1.8 million, payable over two years. Cash Flow: Operating at cash flow breakeven with incremental expenses offset by dedicated funding. Non-GAAP Loss: $688,000 for the fourth quarter, offset by NIH grant proceeds of $900,000. Management Service Income: $3.2 million from Lucid Diagnostics for the quarter. Operating Expenses: Approximately $5.2 million, including $700,000 in stock-based compensation. GAAP Net Income: $1.3 million or $0.12 per common share on a diluted basis for the quarter. Non-GAAP Operating Expenses: $4.2 million for the fourth quarter. Warning! GuruFocus has detected 3 Warning Signs with PAVM. Release Date: March 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. PAVmed Inc (NASDAQ:PAVM) successfully completed a strategic transformation to stabilize its corporate structure and balance sheet, positioning the company for sustainable growth. Lucid Diagnostics, a subsidiary of PAVmed Inc (NASDAQ:PAVM), achieved a 45% growth in test volume quarter-on-quarter, generating $1.2 million in revenue. The company secured its first positive commercial insurance coverage policy for EsoGuard with Highmark Blue Cross Blue Shield in New York. PAVmed Inc (NASDAQ:PAVM) strengthened its balance sheet through long-term debt refinancing and a registered direct common stock offering, extending its cash runway. Veris Health, another subsidiary, completed a private placement financing with gross proceeds of $2.4 million, reflecting strong investor confidence in its long-term commercial potential. PAVmed Inc (NASDAQ:PAVM) faces uncertainties related to forward-looking statements, which are subject to known and unknown risks that could affect actual results. The company is still awaiting a response from the MolDX Group regarding Medicare coverage for EsoGuard, which introduces uncertainty in reimbursement timelines. PAVmed Inc (NASDAQ:PAVM) has ongoing discussions with financial and strategic investors for direct investment in PortIO Corp, indicating a need for additional funding. The deconsolidation of Lucid Diagnostics from PAVmed Inc (NASDAQ:PAVM)'s financial statements has led to complexities in financial reporting and understanding historical data. The company is dependent on securing funding for Veris Health and PortIO to cover incremental development costs, which could impact future operations if not obtained. Q: Can you provide details on the Veris Health Care Cancer platform's pilot program with Ohio State and the nature of the contract? A: Lishan Aklog, Chairman and CEO, explained that the engagement with Ohio State is both a commercial and strategic partnership. The contract will involve Ohio State enrolling a substantial number of patients in a registry, which will help in data collection for ongoing improvements and AI development. Ohio State will also be the first site for the initial implantation of the device once FDA cleared. Q: What is the timeline for the implantable device's FDA approval now that funding is secured? A: Lishan Aklog stated that the manufacturing process is being rebooted, and they expect to be ready for submission by the end of this year or early 2026. The FDA has been engaged in pre-submission meetings, and it appears a full-blown clinical trial may not be necessary, which could expedite the process. Q: Are there any competing products for Veris as you engage with other cancer centers? A: Lishan Aklog noted that while there are generic remote patient monitoring tools, Veris is unique as it is specifically designed for cancer patients undergoing systemic therapy. The implantable device is a proprietary technology that will serve as a significant differentiator and barrier to entry for competitors. Q: What is the path to FDA approval for PortIO, and are additional studies required? A: Lishan Aklog explained that PortIO is a new category of device using the intraosseous site for long-term vascular access. The pathway involves a de novo submission, and they plan to launch an IDE study with 50-80 patients, aiming for FDA clearance within two years of the study's start. Q: Can you provide insights into discussions with other institutions for Veris pilot launches and learnings from OSU? A: Lishan Aklog mentioned that they have had meaningful conversations with about a dozen cancer centers and more advanced discussions with four or five. The focus is currently on advancing the implantable device, and they plan to expand pilot sites after its clearance, leveraging data from the OSU engagement. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
